Published 3 hours ago • loading... • Updated 3 hours ago
XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation
Summary by The Hamilton Spectator
4 Articles
4 Articles
Coverage Details
Total News Sources4
Leaning Left3Leaning Right1Center0Last Updated75% Left
Bias Distribution
- 75% of the sources lean Left
75% Left
L 75%
R 25%
Factuality
To view factuality data please Upgrade to Premium









